Shares of Pacific Biosciences of California (NASDAQ:PACB) ended Wednesday session in green amid volatile trading. The shares closed up +0.19 points or 2.16% at $9.00 with 441,946.00 shares getting traded. Post opening the session at $8.84, the shares hit an intraday low of $8.80 and an intraday high of $9.13 and the price vacillated in this range throughout the day. The company has a market cap of $817.60 million and the numbers of outstanding shares have been calculated to be 91.88 million shares.
Pacific Biosciences of California (PACB) designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The companys single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes biochemical sequencing reactions.
Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) ended Wednesday session in red amid volatile trading. The shares closed down -0.07 points or -0.15% at $45.19 with 9.51 million shares getting traded. Post opening the session at $45.79, the shares hit an intraday low of $44.60 and an intraday high of $45.95 and the price vacillated in this range throughout the day. The company has a market cap of $48.15 billion and the numbers of outstanding shares have been calculated to be 1.01 billion shares.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) announced that it has agreed to sell assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Limited (a subsidiary of Intas Pharmaceuticals Ltd) for an agreed value of GBP 603 million, subject to final approval from the European Commission.
The divestment of certain specified Actavis Generics assets and operations in the UK and Ireland was part of an undertaking that Teva made to the European Commission in the context of the review of the acquisition of Actavis Generics by Teva earlier this year. The sale will include a portfolio of generic medicines plus a manufacturing plant in Barnstaple, England. Teva retains a number of Actavis non-overlapping generic products plus certain specialty medicines and OTC (over-the-counter) products, which have been added to Teva’s existing operations.
“The sale has been a success for Teva in that we have satisfied the EU Commission’s sale requirements for these businesses, subject to their final approval, and agreed on a good price for the assets. With the assets that it will retain, Teva will create an even stronger operation in the UK and Ireland,” commented Siggi Olafsson, President & CEO Global Generic Medicines Teva. “Teva is the leading provider of medicines to the UK National Health Service, and the addition of the retained Actavis assets strengthens our ability to be the partner of choice in these countries while preserving strong and healthy competition in a competitive marketplace.”